Role of modeling in pharmacotherapeutics

Breast Cancer and Molecular Medicine

Volumn , Issue , 2006, Pages 3-27

  Norton, Larry ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865321858     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-28266-2_1     Document Type: Chapter

References (43)

1. DeVita, V., Principles of cancer management: Chemotherapy, in Cancer: Principles and Practice of Oncology, V.T. De Vita, S. Hellman, and S. Rosenberg, Editors. 1997, J.B. Lippincott Co.: Philadelphia. p. 337-347
2. Skipper, H.E., Laboratory models: The historical perspective. Cancer Treatment Rep, 1986. 70: P. 3-7
3. Skipper, H., F.J. Schabel, and W. Wilcox, Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemotherapy Reports, 1964. 35: P. 1
4. Luria, S. and M. Delbruck, Mutations of bacteria from virus sensitivity to virus resistance. Genetics, 1943. 28: P. 491-511
5. DeVita, V., R. Young, and G. Canellos, Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer, 1975. 35: P. 98-110
6. Cannellos, G.P., V.T. DeVita, G.L. Gold, et al., Cyclical combination chemotherapy for advanced breast cancer. British Medical Journal, 1974. 1(901): P. 218-220
7. Sledge, G.W., D. Neuberg, P. Bernardo, et al., Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). J Clin Oncol, 2003. 21(4): P. 588-592
8. Henderson, I.C., D.A. Berry, G.D. Demetri, et al., Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol, 2003: P. JCO.2003.02.063
9. Fisher, B., S. Anderson, A. DeCillis, et al., Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol, 1999. 17(11): P. 3374-3388
10. Fisher, B., S. Anderson, D. Wickerham, et al., Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol, 1997. 15: P. 1858-1869
11. Winer, E., D. Berry, D. Duggan, et al., Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from calgb 9342. Proceedings ASCO, 1998. 17: P. abstract 388
12. Wood, W., D. Budman, A. Korzun, et al., Dose and Dose Intensity Trial of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. New Engl J Med, 1994. 330: P. 1253-1259
13. Budman, D., D. Berry, C. Cirrincione, et al., Dose and dose intensity as determinants of outcome in the adjvuant treatment of breast cancer. JNCI, 1998. 90(16): P. 1205-11
14. Fisher, B., C. Redmond, D.L. Wickerham, et al., Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. Journal of Clinical Oncology, 1989. 7: P. 572-582
15. Fisher, B., A.M. Brown, N.V. Dimitrov, et al., Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Breast and Bowel Project B-15. Journal of Clinical Oncology, 1990. 8: P. 1483-1496
16. Group, E.B.C.T.C., Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet, 1998. 352: P. 930-942
17. Norton, L., R. Simon, J. Brereton, et al., Predicting the course of Gompertzian growth. Nature, 1976. 264: P. 542-545
18. Norton, L. and R. Simon, Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treatment Reports, 1977. 61(7): P. 1307-1315
19. Stadtmauer, E., A. O'Neill, L. Goldstein, et al., Phase III Randomized Trial of High-Dose Chemotherapy (HDC) and Stem Cell Support (SCT) Shows No Difference in Overall Survival or Severe Toxicity Compared to Maintenance Chemotherapy with Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) for Women with Metastatic Breast Cancer Who Are Responding to Conventional Induction Chemotherapy: The 'Philadelphia' Intergroup Study (PBT-1). Proc Am Soc Clin Onc, 1999. 18: P. abs 1
20. Antman, K., P. Rowlings, W. Vaughan, et al., High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. Journal of Clinical Oncology, 1997. 15(5): P. 1870-9
21. Vahdat, L. and K. Antman, High-dose chemotherapy with autologous stem cell support for breast cancer. Current Opinion in Hematology, 1997. 4(6): P. 381-9
22. Berry, D.A., G. Broadwater, J.P. Klein, et al., High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry. J Clin Oncol, 2002. 20(3): P. 743-750
23. Norton, L., Implications of kinetic heterogeneity in clinical oncology. Seminars In Oncology, 1985. 12: P. 231-249
24. Nabholtz, J., T. Pienkowski, J. Mackey, et al., Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc. Am Soc. Clin. Onc, 2002. 21: P. abstr# 141
25. Buzdar, A., S. Singletary, V. Valero, et al., Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res, 2002. 8(5): P. 1073-9
26. Goldie, J.H. and A.J. Coldman, A mathematical model for relating drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports, 1979. 63: P. 1727-1733
27. Goldie, J.H., A.J. Coldman, and G.A. Gudauskas, Rationale for the use of alternating noncross-resistant chemotherapy. Cancer Treatment Reports, 1982. 66(3): P. 439-449
28. Norton, L. and R. Simon, The Norton-Simon hypothesis revisited. Cancer Treatment Reports, 1986. 70: P. 163-169
29. Bonadonna, G., M. Zambette, and P. Valagussa, Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. The Journal of the American Medical Association, 1995. 273(7): P. 542-547
30. Mamounas, E., J. Bryant, B. Lembersky, et al., Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Onc, 2003: P. Abstr # 12
31. Perloff, M., L. Norton, A. Korzun, et al., Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a noncross-resistant: A CALGB study. Journal of Clinical Oncology, 1996. 14: P. 1589-98
32. Crown, J., G. Raptis, N. Hamilton, et al., High-dose chemotherapy of breast cancer: Current status and developmental strategies. Eur J Cancer, 1995. 31A: P. 809-811
33. Rodenhuis, S., M. Bontenbal, L. Beex, et al., Randomized Phase III Study of High-Dose Chemotherapy with Cyclophosphamide, Thiotepa and Carboplatin in Operable Breast Cancer with 4 or More Axillary Lymph Nodes. Proc. Am Soc. Clin. Onc, 2000. 19: P. abs. 286
34. Peters, W., G. Rosner, J. Vredenburgh, et al., A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Onc, 1999. 18: P. Abs #2
35. Bergh, J., T. Wiklund, B. Erikstein, et al., Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet, 2000. 356(9239): P. 1384-1391
36. Hudis, C., A. Seidman, J. Baselga, et al., Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy. J Clin Oncol, 1999. 17(1): P. 93
37. Hudis, C., M. Fornier, L. Riccio, et al., 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study. J Clin Oncol, 1999. 17(4): P. 1118
38. Fornier, M.N., A.D. Seidman, M. Theodoulou, et al., Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res, 2001. 7(12): P. 3934-41
39. Gabrilove, J., A. Jakubowski, H. Scher, et al., Effect of granulocyte colony-stimulating factor on neutropenia associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New England Journal of Medicine. 318(22):1414-22, 1988., 1988. 318(22): P. 1414-22
40. Citron, M.L., D.A. Berry, C. Cirrincione, et al., Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 2003: P. JCO.2003.09.081
41. Fisher, B., S. Anderson, A. DeCillis, et al., Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. Journal of Clinical Oncology, 1999. 17: P. 3374-88
42. Haskell, C., S. Green, G. Sledge, et al., Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A-C) in breast cancer patients with 0-3 positive nodes (intergroup 0137). Proc. Am Soc. Clin. Onc, 2002. 21: P. abstract 142
43. Case, D., R. Bukowski, R. Carey, et al., Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst, 1993. 85: P. 801-06